Application of long-chain non-coding RNA molecule in diagnosis and/or treatment of triple-negative breast cancer

A triple-negative breast cancer, long-chain non-coding technology, used in DNA/RNA fragments, medical preparations containing active ingredients, recombinant DNA technology, etc. HER2-targeted therapy, unclear pathogenesis of triple-negative breast cancer, etc.

Active Publication Date: 2021-03-30
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The pathogenesis of triple-negative breast cancer is unclear, and there is a lack of specific therapeutic targets, making treatment decisions very passive
Triple-negative breast cancer lacks opportunities for endocrine therapy and anti-HER2 targeted therapy, and ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of long-chain non-coding RNA molecule in diagnosis and/or treatment of triple-negative breast cancer
  • Application of long-chain non-coding RNA molecule in diagnosis and/or treatment of triple-negative breast cancer
  • Application of long-chain non-coding RNA molecule in diagnosis and/or treatment of triple-negative breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1: Detection of expression of long non-coding RNA (ENST00000496842) in cancer tissue and serum of patients with triple-negative breast cancer

[0056] 1. Extraction of tissue total RNA by Trizol method

[0057] (1) Sample source

[0058] Triple-negative breast cancer and paracancerous tissue samples were obtained from the Cancer Hospital of the Chinese Academy of Medical Sciences. Fresh tissues were stored in liquid nitrogen in order to obtain sufficient and complete genes, and there were complete medical written records and follow-up records. Breast cancer cell lines ZR-75-1, MCF-7, T47D, SK-BR-3, MDA-MB-468, HCC1937, MDA-MB-231, CAL-51 were selected for lncRNA chip detection, screening and triple negative Breast cancer-associated lncRNAs. Increase in normal breast epithelial cells MCF-10A, breast cancer cell lines ZR-75-1, SK-BR-3, MCF-7, T47D, HCC1937, MDA-MB-468, MDA-MB-231, CAL-51, verification Chip results. 125 cases of frozen fresh tissue samples were...

Embodiment 2

[0101] Example 2: Treatment of triple-negative breast cancer cells with inhibitors of long non-coding RNA (ENST00000496842) inhibits biological effects of invasion, migration and proliferation

[0102] 1. Experimental steps

[0103] (1) Cell culture

[0104] Human triple-negative breast cancer cell lines: ZR-75-1, MCF-7, T47D, SK-BR-3, MDA-MB-468, HCC1937, MDA-MB-231, CAL-51, DMEM medium (Gibco) , containing 10% fetal bovine serum (FBS, Gibco), cultured at 37°C, 5% CO2.

[0105] Normal mammary epithelial cells: MCF-10A, DMEM / F12 (1:1) medium (Gibco), 5% horse serum (Shanghai Shenggong), sequentially added insulin (10ug / ml), epidermal growth factor (20ng / ml ), cholera toxin (100ng / ml), hydrocortisone (0.5ug / ml), 37°C, 5% CO 2 to cultivate.

[0106] (2) Transient cell transfection

[0107] siRNA transfection was performed using Lipofectamine 2000 (Invitrogen, Cat. No. 11668019) reagent.

[0108] si lncRNA transient transfection:

[0109] Sequence of si long non-coding RNA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of a long-chain non-coding RNA molecule in diagnosis and/or treatment of triple-negative breast cancer. Specifically, the invention relates to application of aninhibitor of a long-chain non-coding RNA (ENST00000496842) molecule in preparation of a medicine for treating triple-negative breast cancer. On the other hand, the invention relates to application ofone or more primers and/or probes for specifically detecting the expression level of long-chain non-coding RNA (ENST00000496842) in preparation of a reagent for diagnosing and/or prognosing triple-negative breast cancer.

Description

technical field [0001] The invention relates to the technical field of diagnosis and / or treatment of triple negative breast cancer. It specifically relates to the use of long-chain non-coding RNA (ENST00000496842) molecules in diagnosing and / or treating triple-negative breast cancer. Background technique [0002] Triple-negative breast cancer refers to breast cancer with negative expression of ER, HER2 and PR, accounting for 10-15% of all breast cancers. Compared with other types, it has unique morphology, substructure, and immunohistochemical characteristics, and is prone to early recurrence, distant metastasis, and poor clinical prognosis. The five-year survival rate is less than 15%. The proportion is on the rise. The pathogenesis of triple-negative breast cancer is unclear, and there is a lack of specific therapeutic targets, so treatment decisions are very passive. Therefore, elucidating the molecular mechanism of the occurrence and development of triple-negative bre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6886C12N15/113A61K31/7088A61P35/00A61P15/14
CPCC12Q1/6886C12N15/113A61P35/00A61P15/14C12Q2600/158C12Q2600/178C12Q2600/118C12N2310/113
Inventor 宋咏梅詹启敏赵梓彤
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products